Research Papers
Monte Carlo dosimetric analyses on the use of 90Y-IsoPet intratumoral therapy in canine subjects
Mislav Bobić , Carlos Huesa-Berral , Jack F Terry , Louis Kunz, Jan Schuemann , Darrell R Fisher, Charles A Maitz, Alejandro Bertolet
Abstract
Purpose: To investigate different dosimetric aspects of90Y-IsoPet™ intratumoral therapy in canine soft tissue sarcomas, model the spatial spread of the gel post-injection, evaluate absorbed dose to clinical target volumes, and assess dose distributions and treatment efficacy. Approach. Six canine cases treated with90Y-IsoPet™ for soft tissue sarcoma at the Veterinary Health Center, University of Missouri are analyzed in this retrospective study. The dogs received intratumoral IsoPet™ injections, following a grid pattern to achieve a near-uniform dose distribution in the clinical target volume. To read more click the link below...
Radiation Safety for Yttrium-90-polymer Composites (RadioGel®) in Therapy of Solid Tumors
Darrell R. Fisher
Abstract
Yttrium-90 (90Y)-polymer composite (RadioGel®) is a new cancer therapeutic agent for treating solid tumors by direct interstitial injection. The 90Y-composite comprises insoluble, microscopic yttrium-phosphate particles carried by a sterile, injectable water-polymer (hydrogel) solution that can be placed directly by needle injection into solid tumors. The yttrium-90-RadioGel™ agent was designed to provide a safe, effective, localized, high-dose beta radiation for treating solid tumors. The properties of 90Y-RadioGel® also make it a relatively safe agent for health care personnel who prepare, handle, and administer the material. The purpose of this work was to demonstrate and characterize radiation safety of the injectable 90Y-RadioGel® therapeutic agent. To read more click the link below...
Direct Interstitial Treatment of Solid Tumors Using
an Injectable Yttrium-90-Polymer Composite
Darrell R. Fisher, Janean Fidel, and Charles A. Maitz
Abstract
Purpose: Yttrium-90 (90Y)-polymer composite (RadioGel®) may be administered directly into cancerous tissues to deliver highly localized beta radiation for therapy. In a dose-escalation study, the authors investigated the feasibility of treating feline and canine soft-tissue sarcomas as a model for nonresectable solid tumors in humans to gain clinical experience and to identify optimal methods for placing the composite uniformly within target tumor tissue. To read more click the link below...